Bupivacaine is a widely used local anesthetic agent.
As an implant, bupivacaine is indicated in adults for placement into the surgical site to produce postsurgical analgesia for up to 24 hours following open inguinal hernia repair.
Bupivacaine, in liposome suspension, is indicated in patients aged 6 years and older for single-dose infiltration to produce postsurgical local analgesia. In adults, it is also indicated as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.
Bupivacaine, in combination with meloxicam, is indicated for postsurgical analgesia in adult patients for up to 72 hours following foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.
Bupivacaine, alone or in combination with epinephrine, is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Specific concentrations and presentations are recommended for each type of block indicated to produce local or regional anesthesia or analgesia. Finally, its use is not indicated in all blocks given clinically significant risks associated with use.
DMC Surgery Hospital, Madison Heights, Michigan, United States
Methodist Hospital, Houston, Texas, United States
University of Miami, Dept. Anesthesiology, Miami, Florida, United States
Tampa General Hospital, Tampa, Florida, United States
Mercy Medical Center, Des Moines, Iowa, United States
UTCOM Chattanooga Department of Plastic Surgery, Chattanooga, Tennessee, United States
Clinique Saint-Luc Bouge, Bouge, Namur, Belgium
Erciyes University Medical Faculty, Kayseri, Turkey
Yale New Haven Hospital, New Haven, Connecticut, United States
Faculty of medicine, Cairo University, Cairo, Egypt
Cleveland Clinic, Cleveland, Ohio, United States
King Fahd Hospital of Dammam University, Al Khubar, Eastern, Saudi Arabia
Dammam University, Al Khubar, Eastern, Saudi Arabia
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.